Licensing and Regulatory Affairs
Dear Licensed Prescribers and Dispensers:
This communication is being provided to inform you of a recent guidance that has been issued by the US Food & Drug Administration (FDA) for emergency use of chloroquine phosphate and hydroxychloroquine sulfate, as described in the Scope of Authorization section of the FDA letter (Section II) for the treatment of COVID-19.
LARA appreciates the essential role of our prescribers and dispensers and recognizes their ability to make proper clinical decisions including following responsible prescribing and dispensing practices. LARA thanks all of the dedicated licensed health professionals and others who continue to provide the best possible care for Michigan’s citizens during this state of emergency.
Director, Bureau of Professional Licensing